Abstract: Provided herein are pharmaceutical compositions, each comprising a phenylsulfonamide, for example, a compound of Formula I, or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; and a pharmaceutically acceptable excipient. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a neurodegenerative disease.

Abstract: The oil-in-water type emulsified cosmetic includes: (A) a powder, (B) a water-soluble thickener, and (C) a surfactant, wherein the content of the component (A) is 1% to 30% by mass based on the total amount of the cosmetic, the component (A) contains (A1) an N-acyl acidic amino acid-treated powder, the component (C) contains (C1) a solid nonionic surfactant having a hydrophile-lipophile balance (HLB) value of less than 7 and (C2) a surfactant having an HLB value of 7 or greater, and the mass ratio [(C1):(C2)] between the component (C1) and the component (C2) is 1.5:1 to 30:1.

Abstract: An antiseptic composition for use as a topical skin sanitizer or as a surface disinfectant includes Populus tremuloides Bark Extract and/or Ribes Nigum Fruit Extract in an amount of from about 0.1 to about 50 weight percent effective as a broad spectrum antiseptic and antimicrobial agent. The composition includes an aqueous medium and/or one or more oils. The amount of the aqueous medium is from 45 to about 95 weight percent. The amount of oils is from 0.03 to about 50 weight percent. The composition may also include up to about 1 weight percent of one or more soothing agents; up to about 5 weight percent of one or more thickeners; and up to about 38 weight percent of one or more emulsifiers. The composition does not contain alcohols, chlorinated compounds, iodine, or phenols.

Abstract: This disclosure provides methods of manufacturing large-scale blended preparations comprising one or more amino acids wherein the preparations have certain properties.

Abstract: Disclosed herein are therapeutic constructs including a delivery particle, at least one mitotic kinase inhibitor, and at least one immune checkpoint inhibitor. Also disclosed are therapeutic constructs including a mitotic kinase inhibitor, an immune checkpoint inhibitor, and a chemical linker. These therapeutic constructs cause cancer death by both therapeutic and immune effects and promote targeted delivery of more therapeutics to the surviving cancer cells in a positive feed-back loop. They enhance therapeutic index of free drugs and can be used intratumorally or systemically. This strategy can treat broad cancer types and is particular useful for cancer without obvious receptors for cancer-targeted delivery of otherwise toxic therapeutics.

Abstract: Zinc oxide particles are prepared as a dry powder through a vapor phase formed by a plasma process, or by introducing defects into stoichiometric zinc oxide particles in a liquid carrier through mechanical stress. The zinc oxide has an O:Zn ratio of at least 0.99, an average particle size of 10 to 300 nm, and a sufficient concentration of oxygen vacancies and zinc vacancies to give a dispersion of the particles in C12-C15 alkyl benzoate an orange to tan color corresponding to a ?E value of at least 15 in a Dispersion Color Test. The particles contain no aggregates and have no detectable particles 500 nm or larger, on a number-weighted basis.

Abstract: The present invention relates to methods of determining the levels of 3-methylhistidine before and after a meal in a companion animal, wherein the meal is a pet foodstuff having a particular protein to fat ratio, which is useful in decreasing the levels of 3-methydlhistidine post-prandially and having the beneficial effects as described herein. The pet foodstuff comprises a ratio of protein to fat of 1:0.27 to 1:0.63 on a gram:gram as fed or dry matter basis. The pet foodstuff described is fed to a companion animal for use in reducing and/or preventing sarcopenia. The present invention also relates to methods of feeding the pet foodstuff described and/or dietary regimes to provide the companion animal with the benefit of reducing and/or preventing sarcopenia.

Abstract: In one aspect, the present disclosure provides microparticles that are configured to release a first drug over a first time period and to release a second drug over a second time period, wherein a lag period of substantially no drug release occurs between the first and second time periods. In other aspects, the present disclosure pertains to the use of such microparticles in delivery systems and methods of treatment. In another aspect, the present disclosure pertains to drug delivery systems that comprising a folded inflatable drug delivery balloon that comprises folds and microparticles positioned within the folds.

Abstract: A composition, comprising: a physiologically-acceptable polydimethylsiloxane having a surface; and one or more normal C6-C20NR1R2 saturated amine, salt thereof, or combination thereof, in contact with the polydimethylsiloxane, the surface, or both, wherein R1 and R2 may be same or different and independently selected from H, —CH3, —CH2CH3, —CH2CH2CH3, or combination thereof.

Abstract: Various embodiments disclosed relate to drug-coated balloon catheters for treating strictures in body lumens and methods of using the same. A drug-coated balloon catheter for delivering a therapeutic agent to a target site of a body lumen stricture includes an elongated balloon having a main diameter. The balloon catheter includes a coating layer overlying an exterior surface of the balloon. The coating layer includes one or more water-soluble additives and an initial drug load of a therapeutic agent.

Abstract: Various embodiments disclosed relate to drug-coated balloon catheters for treating strictures in body lumens and methods of using the same. A drug-coated balloon catheter for delivering a therapeutic agent to a target site of a body lumen stricture includes an elongated balloon having a main diameter. The balloon catheter includes a coating layer overlying an exterior surface of the balloon. The coating layer includes one or more water-soluble additives and an initial drug load of a therapeutic agent.

Abstract: Disclosed is a non-spherical microcapsule comprising a core comprising fatty ester having a melting point of at least 30° C. and a benefit agent; a shell comprising nanoparticles having a diameter of 10 to 300 nm.

Abstract: The present disclosure relates to hair care systems comprising: (1) a booster composition containing at least one ionic polymer functionalized with at least one carboxylic acid moiety; optionally, at least one compound selected from an alkoxysilane, a nonionic latex polymer, or mixtures thereof; a thickening agent; and a cosmetically acceptable carrier; and (2) a hair treatment composition containing at least one surfactant selected from an anionic surfactant, an amphoteric surfactant, a cationic surfactant, a nonionic surfactant, or mixtures thereof. The hair care systems of the present disclosure can be used to clean and/or condition hair, as well impart frizz control and manageability benefits to hair.

Abstract: The present invention relates to an additive composition for cosmetics material containing vitamin-C, the additive composition improving the feel on the skin of vitamin-C which is an anti-oxidant. High vitamin-C content can cause stinging skin irritation or be sticky to the touch, but the additive composition according to the present invention, when used in cosmetics composition with high vitamin-C content, due to the oil, can reduce irritation and stickiness, as well as provide a moisturizing effect.

Abstract: A system for delivery of a therapeutic agent to a site in mucosal tissue is provided. The system includes a porous, mucoadhesive polymeric matrix having a first and a second opposed surfaces. The matrix is formed by a composition including chitosan. The composition may also include any or all of a hydration promotor, a microparticle adhesion inhibitor, and a microparticle aggregation inhibitor. A plurality of microparticles having an average diameter between 500 nm and 2000 nm are embedded within the matrix. The microparticles contain a therapeutic agent and have a coating around the therapeutic agent. The first surface of the matrix is configured to be attached to the site in the mucosal tissue and the matrix is configured to provide controlled release of the microparticles through the first surface. The coating of the microparticles includes chitosan so as to provide controlled release of the agent from the microparticles.

Abstract: A self-emulsifying bioactive concentrate produced by a process comprising the steps of (a) creating a lysophospholipid concentrate comprised of a de-oiled lecithin source and 0.1% to 10% of an enzyme with having phospholipase A activity, wherein the lysophospholipid concentrate contains greater than 20% lysophosphatidyl-choline; and (b) combining the lysophospholipid concentrate from step (a) with a retinyl ester formed by the reaction of retinol and one or a mixture of unsaturated fatty acid(s).

Abstract: A surgical implant (20) comprises a flexible, areal basic structure (22) having a first face and a second face and being provided with pores (26) extending from the first face to the second face. A barrier layer (24) having a first face and a second face is placed, with its second face, at the first face of the basic structure (2) and attached to the basic structure (22). The barrier layer (24) is deformed into at least part of the pores (26) where it forms, in a respective pore (10), a barrier region (28).

Abstract: A method for suppressing obstruction of meibomian gland in a mammalian subject, the method comprising administering to the mammalian subject an eye drop comprising 0.01 to 0.5% (w/v) of sirolimus or a pharmaceutically acceptable salt thereof as a sole active ingredient, wherein the eye drop is administered to an eye of the mammalian subject 1 to 2 times per day.

Abstract: Methods of entrapping enzymes in chitosan matrices using mild conditions, such as methods that are compatible with the entrapment of acid-sensitive and/or heat sensitive enzymes, are described. The methods can provide biocatalytic materials with high chitosan to enzyme mass ratios where one or more enzymes can remain active and stably entrapped in the chitosan matrix for many months and/or after repeated washings. Also described are materials including a solid chitosan matrix having at least one enzyme stably entrapped therein, including fabrics, textiles and other flexible materials at least partially coated with one or more layer of the solid chitosan matrix having at least one enzyme stably entrapped therein and the use of the materials as biocatalyst systems, for example in biogas upgrading and other applications.

Abstract: Disclosed herein are compositions comprising insoluble alpha-glucan particles having a high degree of crystallinity and small particle size. For example, the alpha-glucan particles can have a degree of crystallinity of at least about 0.65, and/or an average size of less than a micron. At least 50% of the glycosidic linkages of the insoluble alpha-glucan in the disclosed particles are alpha-1,3 glycosidic linkages. Further disclosed are methods of producing insoluble alpha-glucan particles, as well as their use in various applications and products.